A clinically efficacious Ras inhibitor has eluded drug-discovery efforts for decades. In a paper in Nature, Zimmermann and et al. show that blocking a hole in PDEd that normally engages the lipid tail of Ras disrupts downstream signaling, pointing to a potentially promising route to develop Ras inhibitors for cancer treatment.
Activating Ras mutations are found very frequently in human cancers (Schubbert et al., 2007) . In particular, mutations in the K-Ras isoform are prevalent in cervical, lung, pancreatic, and colorectal cancers and are associated with a poor prognosis. Unfortunately, no clinically viable drugs have yet been developed to inhibit Ras signaling directly. Ras binds to guanosine diphosphate and guanosine triphosphate (GTP) with picomolar affinity, making it challenging to develop competitive inhibitors for the nucleotidebinding pocket, given the abundance of free nucleotides in the cell. An intense effort to block Ras maturation by targeting Ras farnesyl transferases appears to have stalled. Given the demand for small molecule inhibitors that target Ras signaling, investigators have been searching for alternative approaches to achieve this end. In a recent issue of Nature, Zimmermann et al. (2013) report exciting new findings on the inhibition of Ras signaling by targeting the Ras-binding protein PDEd, which has a deep pocket that appears most welcoming to small molecules (Zimmermann et al., 2013) .
Ras activity arises from the combined actions of guanine nucleotide exchange factors, which cause the release of bound nucleotide and subsequent binding of GTP, and GTPase activating proteins (GAPs) that accelerate hydrolysis of Rasbound GTP (Cherfils and Zeghouf, 2013) . Oncogenic Ras mutations subvert GAPinduced GTP hydrolysis, leading to constitutive signaling. An additional level of regulation is made possible by the fact that lipid modifications at the C terminus of Ras-family proteins are necessary for function. These lipid anchors control the final destination within the cell of different Ras isoforms and limit the free diffusion of the proteins through the cytoplasm. PDEd controls the intracellular localization of Ras-like proteins by binding to their farnesyl tails ( Figure 1 ). In this way, PDEd enhances the cytoplasmic diffusion of Ras, allowing it to distribute to the proper subcellular compartments where signaling is initiated (Chandra et al., 2012; Nancy et al., 2002) .
PDEd was discovered originally as a subunit of phosphodiesterase 6 (PDE6) in photoreceptor cells, where it likely plays a role in binding to the lipid tails of the PDE6 catalytic subunits. The farnesyl anchor at the C terminus of Ras and other proteins is recognized by a hydrophobic hole in the immunoglobulin-like b sandwich fold of PDEd (Ismail et al., 2011) . The action of PDEd is similar to that of Rho guanine nucleotide dissociation inhibitors (GDIs) (Hanzal-Bayer et al., 2002) , which also use a b sandwich fold to recognize the geranylgeranyl moiety of the Rho GTPase. RhoGDIs employ a second domain to contact the switch I and switch II regions of the GTPase (Garcia-Mata et al., 2011), but this helical region is not conserved in PDEd (Ismail et al., 2011) . Because the nucleotidebound state of the G protein is not sensed by PDEd, the interaction between the two proteins is regulated by other mechanisms. For example, the binding of Arl2$GTP or Arl3$GTP allosterically induces PDEd to relinquish its cargo (Hanzal-Bayer et al., 2002; Ismail et al., 2011) , as demonstrated by structural and biophysical studies.
Given the importance of PDEd in proper Ras localization, Zimmermann and colleagues speculate that compounds designed to disrupt Ras binding to PDEd might have a profound and desirable effect on Ras signaling. By using a highthroughput screen, they uncover a series of benzimidazole molecules that inhibit the Ras-PDEd interaction by plugging the farnesyl-binding cavity. Structural analysis plays a key role in optimizing these compounds because it reveals that two benzimidazole molecules bind side-by-side to PDEd. This unexpected finding motivates the synthesis of additional analogs that connect the benzimidazole moieties via short linkers, leading to more potent inhibitors with low-nanomolar affinity for PDEd in vitro.
Using fluorescence lifetime imaging microscopy-based measurements, the authors show that one such compound (termed Deltarasin) disrupts the interaction between PDEd and K-Ras in cells and results in the redistribution of K-Ras to endomembranes rather than the plasma membrane. Furthermore, Deltarasin increases cell death of a cancer cell line that relies on K-Ras for survival but is not toxic to cells that survive independently of K-Ras signaling.
Previous efforts to identify inhibitors of Ras signaling have employed a range of different strategies (Baines et al., 2011) . The discovery of the enzymes responsible for modification and lipidation of the C-terminal region of Ras generated tremendous excitement for attempts to inhibit this machinery. However, the processing enzymes have many protein targets, and inhibition of the Ras farnesyl transferase leads to compensation by a second lipid-modifying enzyme. Other screens have focused on downstream effectors of Ras such as Raf kinase.
Although this strategy is promising in the treatment of some cancers, Ras activates many other effectors that promote oncogenesis. Recent searches for inhibitors that target Ras more directly by using a fragment-based lead discovery approach have led to the identification of compounds that bind to a pocket on Ras adjacent to the switch I and switch II elements (Maurer et al., 2012) . Molecules from this screen were shown to inhibit SOS-mediated nucleotide exchange in vitro but are severely lacking in potency.
The work from Zimmermann and coworkers represents a novel strategy for combating oncogenic Ras mutations. It remains to be seen if inhibitors of the Ras-PDEd interaction will succumb to the same pitfalls as other Ras-targeting therapies. It is encouraging to note that Deltarasin does not bind to other GDIlike solubilizing proteins. Additionally, Deltarasin reduces the growth rate of tumor-cell xenografts in mice. However, because PDEd primarily interacts with the farnesyl group of K-Ras, Deltarasin may also disrupt signaling by other GTPases such as Rheb or Rap in cells. Regardless, this work represents an exciting new avenue in the pursuit of Ras inhibitors for the treatment of cancers and developmental diseases because the hole in PDEd seems so eminently druggable. It is also gratifying to see how the continuing investigations into the mysteries of Ras signaling have illuminated this particular target and might reveal others in the future.
